Feedback expecting surge in second half revenues

Feedback plc (LON:FDBK) expects to see a substantial increase in revenue from its TexRAD software in the second half of the current financial year. The medical imaging firm has previously reported a significant number of purchase orders for research versions of TexRAD in the first half of its current financial year (i.e. to the end of November), but investors hoping this would show through immediately in the interim results were disappointed. The majority of the installations were done just before the end of the reporting period so the sales made only a modest contribution to revenue. Nevertheless, Feedback trimmed its half-year loss before tax to £130,000 from a loss the year before of £155,000 on revenue that dipped to £204,000 from £225,000. "We are encouraged by the continued strong interest shown in TexRAD and the number of research papers being published, which highlight its numerous potential applications, particularly in areas such as liver, prostate and adrenal cancers," the company said.